Novo Nordisk A/S (NYSE:NVO) Shares Sold by Global X Japan Co. Ltd.

Global X Japan Co. Ltd. decreased its position in Novo Nordisk A/S (NYSE:NVO) by 10.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,105 shares of the company’s stock after selling 1,929 shares during the quarter. Global X Japan Co. Ltd.’s holdings in Novo Nordisk A/S were worth $1,118,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL grew its stake in shares of Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock valued at $27,000 after acquiring an additional 300 shares in the last quarter. Park Square Financial Group LLC acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth approximately $29,000. Transce3nd LLC acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth approximately $33,000. CX Institutional acquired a new stake in shares of Novo Nordisk A/S during the first quarter worth approximately $36,000. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth approximately $39,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on NVO shares. Hsbc Global Res raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, April 28th. Stifel Nicolaus downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. BNP Paribas initiated coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an “underperform” rating for the company. Finally, Dbs Bank lowered Novo Nordisk A/S to a “sell” rating in a research report on Friday, April 25th. Two analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and a consensus target price of $112.00.

Novo Nordisk A/S Trading Down 0.4%

NYSE NVO opened at $74.03 on Thursday. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15. The company has a 50-day simple moving average of $67.98 and a 200-day simple moving average of $79.17. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. The firm has a market capitalization of $332.19 billion, a PE ratio of 21.90, a price-to-earnings-growth ratio of 1.33 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts’ consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The company had revenue of $11.87 billion during the quarter. On average, equities analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.